GFI1 and acute myeloid leukemia: To provide further evidence that GFI1’s activity is the predominant target of LSD1 pharmacologic inhibition in AML cells, we performed genetic KD of GFI1 in THP1 AML cells and observed a loss of clonogenic potential with the upregulation of CD86 with two separate KD constructs (Figures 7A–7C).